Increasing Transparency in Author Contributions to Manuscripts: Enhanced Policy on Ghost and Honorary Authorships

Alex A. Adjei; Sai Hong Ignatius Ou; Cheryl Ho; Jean Louis Pujol; Sumithra Mandrekar; Emily Stone; Andrea Bezjak; D. Ross Camidge

doi:10.1016/j.jtho.2021.03.005

Increasing Transparency in Author Contributions to Manuscripts: Enhanced Policy on Ghost and Honorary Authorships

Alex A. Adjei, Sai Hong Ignatius Ou, Cheryl Ho, Jean Louis Pujol, Sumithra Mandrekar, Emily Stone, Andrea Bezjak, D. Ross Camidge

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	706-708
Number of pages	3
Journal	Journal of Thoracic Oncology
Volume	16
Issue number	5
DOIs	https://doi.org/10.1016/j.jtho.2021.03.005
State	Published - May 2021

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.jtho.2021.03.005

Cite this

@article{4ef76282b81a452684f658fd23541adf,

title = "Increasing Transparency in Author Contributions to Manuscripts: Enhanced Policy on Ghost and Honorary Authorships",

author = "Adjei, {Alex A.} and {Ignatius Ou}, {Sai Hong} and Cheryl Ho and Pujol, {Jean Louis} and Sumithra Mandrekar and Emily Stone and Andrea Bezjak and Camidge, {D. Ross}",

note = "Funding Information: Disclosure: Dr. Ou reports receiving personal fees from Pfizer, Merck, Takeda, AstraZeneca, Roche/Genentech, Daiichi-Sankyo, Janssen/Johnson & Johnson, and X-Covery LLC and other fees from Turning Point Therapeutics and Elevation Oncology outside of the submitted work. Dr. Camidge reports providing advisory role: ad hoc advisory boards/consultations for the following: 2021: AbbVie, Apollomics (safety review committee [SRC]), AstraZeneca (SRC/steering committee), Daiichi Sankyo (interstitial lung disease [ILD] adjudication committee), Elevation (SRC), Kestrel (scientific advisory board [SAB]), Nuvalent (SAB), Seattle Genetics, Takeda, and Turning Point; 2020: Amgen, Anchiarno (SAB), Apollomics (SRC), AstraZeneca, Bio-Thera (data safety monitoring board [DSMB]), Bristol-Myers Squibb, Daiichi Sankyo (ILD adjudication committee), Eisai, EMD Serono, Elevation (SRC), Eli Lilly, GlaxoSmithKline, Helssin, Janssen, Onkure, Mersana, Pfizer, Qilu, Roche, Sanofi, Seattle Genetics, and Takeda; and 2019: Takeda, CBT Pharmaceuticals, Daiichi Sankyo (ILD adjudication committee), G1 Therapeutics (DSMB), Bio-Thera (DSMB), Blueprint, AbbVie, Achilles, BeyondSpring, Apollomics (SRC), 14ner/Elevation (SRC), Archer, EMD Serono, Helssin, Bristol-Myers Squibb, Eli Lilly, Medtronic, and Ribon. The remaining authors declare no conflict of interest.",

year = "2021",

month = may,

doi = "10.1016/j.jtho.2021.03.005",

language = "English (US)",

volume = "16",

pages = "706--708",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "International Association for the Study of Lung Cancer",

number = "5",

}

TY - JOUR

T1 - Increasing Transparency in Author Contributions to Manuscripts

T2 - Enhanced Policy on Ghost and Honorary Authorships

AU - Adjei, Alex A.

AU - Ignatius Ou, Sai Hong

AU - Ho, Cheryl

AU - Pujol, Jean Louis

AU - Mandrekar, Sumithra

AU - Stone, Emily

AU - Bezjak, Andrea

AU - Camidge, D. Ross

N1 - Funding Information: Disclosure: Dr. Ou reports receiving personal fees from Pfizer, Merck, Takeda, AstraZeneca, Roche/Genentech, Daiichi-Sankyo, Janssen/Johnson & Johnson, and X-Covery LLC and other fees from Turning Point Therapeutics and Elevation Oncology outside of the submitted work. Dr. Camidge reports providing advisory role: ad hoc advisory boards/consultations for the following: 2021: AbbVie, Apollomics (safety review committee [SRC]), AstraZeneca (SRC/steering committee), Daiichi Sankyo (interstitial lung disease [ILD] adjudication committee), Elevation (SRC), Kestrel (scientific advisory board [SAB]), Nuvalent (SAB), Seattle Genetics, Takeda, and Turning Point; 2020: Amgen, Anchiarno (SAB), Apollomics (SRC), AstraZeneca, Bio-Thera (data safety monitoring board [DSMB]), Bristol-Myers Squibb, Daiichi Sankyo (ILD adjudication committee), Eisai, EMD Serono, Elevation (SRC), Eli Lilly, GlaxoSmithKline, Helssin, Janssen, Onkure, Mersana, Pfizer, Qilu, Roche, Sanofi, Seattle Genetics, and Takeda; and 2019: Takeda, CBT Pharmaceuticals, Daiichi Sankyo (ILD adjudication committee), G1 Therapeutics (DSMB), Bio-Thera (DSMB), Blueprint, AbbVie, Achilles, BeyondSpring, Apollomics (SRC), 14ner/Elevation (SRC), Archer, EMD Serono, Helssin, Bristol-Myers Squibb, Eli Lilly, Medtronic, and Ribon. The remaining authors declare no conflict of interest.

PY - 2021/5

Y1 - 2021/5

UR - http://www.scopus.com/inward/record.url?scp=85105972719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105972719&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2021.03.005

DO - 10.1016/j.jtho.2021.03.005

M3 - Editorial

C2 - 33896566

AN - SCOPUS:85105972719

SN - 1556-0864

VL - 16

SP - 706

EP - 708

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 5

ER -

Increasing Transparency in Author Contributions to Manuscripts: Enhanced Policy on Ghost and Honorary Authorships

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this